Support The Moscow Times!

Now is the time to support independent reporting from Russia!

Contribute Today

Pharmstandard Sales Up

Despite regulatory tightening, drugmaker Pharmstandard posted a 14.7 percent year-on-year rise in second-quarter sales Thursday, reversing a 33 percent decline the previous quarter.

Pharmstandard's revenue amounted to 8 billion rubles ($244.16 million) in the April-through-June period, against 6.98 billion in the same period last year, the company said.

The growth comes despite a change in regulation of sales of codeine-containing medication, which led to a 54 percent drop in revenue from such products compared with the year earlier. The Russian government banned nonprescription sales of pain relievers containing codeine. First-half sales were still down 13.3 percent from a year ago to 16.2 billion rubles, mainly due to weaker sales of anti-flu drugs in the first quarter.


Read more

Russia media is under attack.

At least 10 independent media outlets have been blocked or closed down over their coverage of the war in Ukraine.

The Moscow Times needs your help more than ever as we cover this devastating invasion and its sweeping impacts on Russian society.